We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
Website: http://www.lesusacanada.org/events/EventDetails.aspx?id=922000&group;=
Many sources of information on biopharmaceutical royalty rates and deal terms rely on either Freedom of Information (FOI) sources from public companies in the United States, which only represent "material" deals that are generally more than five years old, or rely on press releases or public announcements which are often positioned for maximum publicity or promotional impact (i.e., the hyperbole of "BIO Bucks").
The Life Sciences Sectors of LES USA & Canada and LES International have partnered to conduct a landmark GLOBAL survey of royalty rates and deal terms for recent deals conducted in the past two years. The results represent significant information on early stage deals from universities, private biotech companies and deals submitted by international companies outside the USA and Canada.
This landmark global survey is unique for the biopharmaceutical industry. The results presented in this session will be highlights of the Survey Report to be published in February 2017. The findings provide insights certain to raise questions or challenge conventional thinking, especially for contemporary deals in recent and turbulent years.
Speakers:
